ArticleObesity surgery2026
Preoperative GLP-1 Receptor Agonists Exposure and Risk of Postoperative Acute Kidney Injury after Metabolic and Bariatric Surgery: A Retrospective Study.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucagon-like peptide-1 receptor agonists (GLP-1-RAs) are increasingly prescribed for patients with type 2 diabetes mellitus (T2DM) and obesity undergoing metabolic and bariatric surgery (MBS). This study evaluated the association between preoperative GLP-1-RAs exposure and the risk of acute kidney injury (AKI) following MBS.
methodsThis retrospective cohort study utilized the TriNetX Research Network to identify adults with T2DM and a body mass index exceeding 35 kg/m² who underwent elective laparoscopic MBS (2010-2024). Patients were stratified by preoperative GLP-1-RAs exposure and matched using propensity score analysis. The primary outcome was the incidence of AKI within 90 days after surgery, and the secondary outcomes included mortality, intensive care unit (ICU) admission, sepsis, and events of postoperative hyperglycemia (i.e., serum glucose > 180 mg/dL).
resultsAfter propensity score matching, 5,480 patients were included in each cohort. Preoperative GLP-1-RAs exposure was associated with a significantly reduced 90-day AKI risk (1.6% versus 2.3%; hazard ratio [HR]: 0.68, 95% confidence interval [CI] 0.52-0.89, p = 0.005, absolute risk reduction [ARR]:0.73%, number needed to treat [NNT]:137) and 30-day risk (HR: 0.58, p = 0.001). GLP-1-RAs exposure also correlated with a lower risk of postoperative hyperglycemia (24.5% versus 26.6%, HR:0.91, 95% CI: 0.85-0.99, p = 0.013, ARR 2.04%, NNT 49). No significant differences were observed in mortality, ICU admission, or sepsis. Sensitivity analyses confirmed these consistent findings.
conclusionPreoperative GLP-1-RAs exposure was associated with a reduced AKI risk following MBS, with concurrent improvement in perioperative glycemic control. Future randomized controlled studies are required to validate these observational findings and clarify the underlying mechanisms.
Indexed as
Identifiers
41405672What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.